Log in
Enquire now
‌

US Patent 9914708 Benzoimidazol-1,2-yl amides as Kv7 channel activators

Patent 9914708 was granted and assigned to Knopp Biosciences on March, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Knopp Biosciences
Knopp Biosciences
0
Current Assignee
Knopp Biosciences
Knopp Biosciences
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
99147080
Patent Inventor Names
Charles A. Flentge0
Lynn Resnick0
Scott S. Harried0
Steven A. Boyd0
David A. Mareska0
George T. Topalov0
James S. Hale0
Justin K. Belardi0
...
Date of Patent
March 13, 2018
0
Patent Application Number
153395900
Date Filed
October 31, 2016
0
Patent Citations Received
‌
US Patent 11834418 Benzoimidazol-1,2-yl amides as Kv7 channel activators
0
Patent Primary Examiner
‌
Laura L. Stockton
0
Patent abstract

Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9914708 Benzoimidazol-1,2-yl amides as Kv7 channel activators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.